Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Terbutaline sulphate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Bricanyl Turbuhaler M2, Active | ACTIVE_COMPARATOR | Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation |
| Bricanyl Turbuhaler M3, Active | ACTIVE_COMPARATOR | Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation |
| Turbuhaler M2, Placebo | PLACEBO_COMPARATOR | Placebo powder for inhalation |
| Turbuhaler M3, Placebo | PLACEBO_COMPARATOR | Placebo powder for inhalation |
| Name | Type | Description |
|---|---|---|
| Terbutaline sulphate | DRUG | Bricanyl Turbuhaler M2 |
| Placebo for terbutaline sulphate | DRUG | Placebo Turbuhaler M2 |
Inclusion Criteria: - Female and male aged 18 and 65 years. * At least 6 months of documented clinical diagnosis of asthma as defined by GINA 2012 or American Thoracic Society (Expert Panel Report 3 2007) prior to visit 1 * Stable asthmatics on SABA alone, on low dose ICS (200-400 µg budesonide cor...
Terbutaline sulphate is a small molecule used for the treatment of asthma. It is being developed by AstraZeneca PLC as a bronchodilator to relieve symptoms associated with the condition. The drug is currently in Phase 3 clinical development and is administered via inhalation.
Terbutaline sulphate is a beta-2 adrenergic receptor agonist. It works by stimulating beta-2 receptors in the airways, which leads to relaxation of bronchial smooth muscle and relief of bronchospasm in asthma patients. This mechanism helps to improve airflow and reduce asthma symptoms.
Terbutaline sulphate is developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with asthma.
Terbutaline sulphate is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the results will inform potential regulatory submissions for marketing approval.
Terbutaline sulphate has one completed Phase 3 clinical trial registered as NCT02322788. This randomized, double-blind, placebo-controlled study enrolled 95 participants with asthma across Canada, Netherlands, and Sweden. The trial compared the efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg dose levels.
Terbutaline sulphate is the active ingredient in the product Bricanyl. The clinical trial NCT02322788 specifically evaluated Bricanyl Turbuhaler M2 and M3 formulations, which contain terbutaline sulphate. Thus, Bricanyl is a brand name for terbutaline sulphate.